Cargando…
Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study
BACKGROUND: The recommended treatment of Pneumocystis jirovecii pneumonia (PCP) is high-dose trimethoprim–sulfamethoxazole (TMP–SMX) in an equivalent of TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day for 2 or 3 weeks. High rates of adverse events are reported with this dose, which raises the question...
Autores principales: | Creemers-Schild, Dina, Kroon, Frank P., Kuijper, Ed. J., de Boer, Mark G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889633/ https://www.ncbi.nlm.nih.gov/pubmed/26471512 http://dx.doi.org/10.1007/s15010-015-0851-1 |
Ejemplares similares
-
Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
por: Prasad, G. V. Ramesh, et al.
Publicado: (2019) -
Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
por: Ji, Jianlei, et al.
Publicado: (2021) -
Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022) -
A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
por: Lee, Sang Min, et al.
Publicado: (2015) -
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2018)